Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a stronger blood thinner cut repeat stroke risk?

NCT ID NCT07746882

Prevention Sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 05, 2026 · Last updated Aug 06, 2026 · Updated 1 time

Summary

This trial tests whether anticoagulant medications (like rivaroxaban or apixaban) are better than aspirin at preventing a second stroke in people who have had an ischemic stroke of unclear cause. Participants are adults who had a stroke within the past two weeks and show signs that might benefit from stronger blood thinning. The study compares the two approaches over three months to see which is safer and more effective at reducing recurrent strokes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Anticoagulation therapy (rivaroxaban, edoxaban, apixaban, or dabigatran) compared with antiplatelet therapy (aspirin or alternatives)
What this could lead to
If anticoagulants prove more effective, they could become a standard preventive treatment for certain stroke survivors, reducing the risk of another stroke.
What could go wrong
This is a phase 3 trial, but results may not apply to all stroke patients. Anticoagulants carry a risk of bleeding, which could offset benefits in some individuals.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 680 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Nov 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years * Ischemic stroke patients with undetermined etiology, within 14 days of onset, with completed etiological assessment * At least one of the following: 1. Cortical or multi-territorial infarct 2. Recurrent stroke or stroke on antiplatelet therapy 3. Left atrial diameter \>40 mm 4. Left ventricular dysfunction (EF 30-40% or regional wall motion abnormality) 5. Atrial premature beats \>1500/24h Exclusion Criteria: * Stenosis ≥50% in the responsible vessel or high-risk plaque * Identified cardioembolic source * PFO with planned closure * Malignancy * Indication for mandatory anticoagulation/antiplatelet therapy * Active bleeding (intracranial, subarachnoid, gastrointestinal, etc.) * History of intracranial hemorrhage * Current or recent gastrointestinal ulcer * Recent brain or spinal injury/surgery * Known or suspected vascular malformations or aneurysms * Severe renal impairment (CrCl \<30 ml/min) * Liver disease with bleeding risk (Child-Pugh B or C) * Pregnancy or lactation * Other contraindications to anticoagulation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute ischemic stroke are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

ischemic stroke stroke disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute ischemic stroke Stroke

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.